Zymeworks Takes Poison Pill To Block Hostile Bid
Cancer drug developer Zymeworks Inc. on Friday announced a poison pill strategy to block a $773 million hostile takeover bid by All Blue Capital, saying it substantially undervalued the company....To view the full article, register now.
Already a subscriber? Click here to view full article